PRESS-RELEASE filed Jul 9, 2026 at 16:01 ET
Nurix reported Q1 FY2026 revenue of $9.0M (consensus $15.3M, -41% miss) and EPS of -$0.81 vs consensus -$0.72 (-12.5% miss) following a year-ago quarter that included $30M in license fees. The revenue miss is largely explained by the absence of the prior-year Sanofi license payments, but the operational spend ramp (R&D up 12% YoY) drove net loss to -$89.5M vs -$43.5M. The dominant positive event is the global Roche collaboration for bexobrutideg, which brings a $700M near-term cash infusion (expected closing in Q3) and total potential milestones of $2.3B, dramatically extending the cash runway to ~$1.14B pro-forma and validating the BTK degrader platform across oncology, immunology, and neurology.